We conducted a literature review to evaluate global antifungal susceptibility patterns in Candida auris, an emerging multidrug-resistant fungal pathogen of growing clinical concern. A comprehensive search of the literature identified 29 studies reporting min-imum inhibitory concentrations (MICs) and resistance rates across major antifungal classes. Across studies, C. auris demonstrated consistently high resistance to fluconazole, with variable resistance observed among other azoles, amphotericin B, and echi-nocandins, alongside evidence of emerging multidrug resistance. These findings reflect significant geographic variability and highlight ongoing challenges in treatment selec-tion due to inconsistent susceptibility profiles and limited standardized breakpoints. Emerging antifungal agents, including ibrexafungerp and manogepix, demonstrate promising activity and may help address current therapeutic gaps. Overall, the global rise in antifungal resistance among C. auris isolates underscores the narrowing range of effective therapeutic options and reinforces the need for continued surveillance, improved susceptibility testing standardization, and development of novel antifungal agents.